122 related articles for article (PubMed ID: 23050411)
21. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
22. Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
Johnson PW
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):316-322. PubMed ID: 27913497
[TBL] [Abstract][Full Text] [Related]
23. Homonymous hemianopsia in a patient with Hodgkin's lymphoma in remission after BEACOPP chemotherapy.
Bruessow C; Karrer U; Gubler J; Pless M
J Clin Oncol; 2012 Apr; 30(12):e130-2. PubMed ID: 22393099
[No Abstract] [Full Text] [Related]
24. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
25. Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):9-10. PubMed ID: 27007004
[No Abstract] [Full Text] [Related]
26. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
27. Hodgkin's lymphoma--the great teacher.
Connors JM
N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
[No Abstract] [Full Text] [Related]
28. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
29. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET for Early Response Assessment in Lymphomas: Part 1-Hodgkin Lymphoma.
Cheson BD; Kostakoglu L
Oncology (Williston Park); 2017 Jan; 31(1):45-9. PubMed ID: 28090622
[TBL] [Abstract][Full Text] [Related]
31. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
Diehl V; Behringer K
Cancer Invest; 2006; 24(4):461-5. PubMed ID: 16777701
[TBL] [Abstract][Full Text] [Related]
32. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group.
Behringer K; Wildt L; Mueller H; Mattle V; Ganitis P; van den Hoonaard B; Ott HW; Hofer S; Pluetschow A; Diehl V; Engert A; Borchmann P;
Ann Oncol; 2010 Oct; 21(10):2052-2060. PubMed ID: 20305034
[TBL] [Abstract][Full Text] [Related]
33. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
Kobe C; Goergen H; Baues C; Kuhnert G; Voltin CA; Zijlstra J; Hoekstra O; Mettler J; Drzezga A; Engert A; Borchmann P; Dietlein M
Blood; 2018 Nov; 132(21):2273-2279. PubMed ID: 30166329
[TBL] [Abstract][Full Text] [Related]
34. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
35. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?
Diehl V; Behringer K
Cancer Invest; 2006 Nov; 24(7):713-7. PubMed ID: 17118782
[TBL] [Abstract][Full Text] [Related]
36. More is not necessarily better when treating Hodgkin's lymphoma.
Connors JM
J Clin Oncol; 2011 Nov; 29(32):4215-6. PubMed ID: 21990411
[No Abstract] [Full Text] [Related]
37. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD; Klapper W; Glehr G; Müller H; Haverkamp H; Thorns C; Hansmann ML; Möller P; Stein H; Rehberg T; von Tresckow B; Reinhardt HC; Borchmann P; Chan FC; Spang R; Scott DW; Engert A; Steidl C; Altenbuchinger M; Rosenwald A
Leukemia; 2021 Dec; 35(12):3589-3593. PubMed ID: 34112956
[No Abstract] [Full Text] [Related]
38. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: a progress report.
Sagar TG; Chandra A; Raman SG
Med Pediatr Oncol; 2003 Jan; 40(1):66-9. PubMed ID: 12426693
[No Abstract] [Full Text] [Related]
39. Greater curability in advanced Hodgkin's disease?
Portlock CS
Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
[No Abstract] [Full Text] [Related]
40. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
